Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials
3 recruiting trials for Nonalcoholic Fatty Liver Disease (NAFLD). Eligibility criteria explained in plain English.
TrialFinderData lists 3 Nonalcoholic Fatty Liver Disease (NAFLD) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Centre hospitalier de l'Université de Montréal (CHUM) (1), Phenomen Pharma (1), Chinese University of Hong Kong (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) (device, 1 trial), followed by Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid).
Track Nonalcoholic Fatty Liver Disease (NAFLD) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced...
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver...
Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in many parts of the world. NAFLD can progress to nonalcoholic steatohepatitis (NASH) and...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Nonalcoholic Fatty Liver Disease (NAFLD), with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Nonalcoholic Fatty Liver Disease (NAFLD), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Nonalcoholic Fatty Liver Disease (NAFLD), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.